Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

tag uveal-melanoma

Immunocore’s Kimmtrak Gets FDA Approval as First Treatment for Rare Eye Cancer and First T Cell Receptor Therapeutic

XTalks

JANUARY 28, 2022

Uveal melanoma is a rare and aggressive type of melanoma of the eye. Uveal melanoma is a rare and aggressive type of melanoma of the eye. As such, unresectable or metastatic uveal melanoma usually has a poor prognosis and until the approval of Kimmtrak, there was no approved treatment.

FDA Approval

FDA Approval Development Licensing Licensing

Immunocore gets EU nod for TCR cancer therapy Kimmtrak

pharmaphorum

APRIL 5, 2022

Kimmtrak (tebentafusp) has been cleared to for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM), mirroring its label in the US. Uveal melanoma is a rare cancer of the eye, which in the majority of patients is localised.

Protein

Protein Sales Drugs Trials

Immunocore’s Kimmtrak Gets FDA Approval as First Treatment for Rare Eye Cancer and First T Cell Receptor Therapeutic

Immunocore gets EU nod for TCR cancer therapy Kimmtrak

Stay Connected